Vanguard Diversified High Growth Index ETF

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Qantas Airways Limited

QAN

Qantas Airways Ltd. engages in international and domestic air transportation services. The company is headquartered in Mascot, New South Wales and currently employs 27,625 full-time employees. The principal activities of the Company include the operation of international and domestic air transportation services and provision of freight services and the operation of a frequent flyer loyalty program. The Company’s segments include Qantas Domestic, Qantas International, Jetstar Group, Qantas Loyalty, and Corporate. Qantas Domestic is a carrier in the Australian domestic market measured by capacity. Qantas Domestic offers on-board Wi-Fi and upgrades to the domestic lounges. Qantas International is a carrier into and out of Australia, also targeting business and premium leisure customers who value the full-service experience. Jetstar Group has domestic and international routes in Australia, joint ventures in Singapore and Japan. Qantas Loyalty is comprised of consumer and SME coalition loyalty programs. Its airline brands operate regional, domestic, and international services.

Betashares Australia 200 ETF

A200

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

Betashares Global Sustainability Leaders ETF

ETHI

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

Incannex Healthcare Limited

IHL

Incannex Healthcare Ltd. is a clinical stage pharmaceutical development company, which engages in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The company is headquartered in Melbourne, Victoria. The company went IPO on 2007-05-23. The firm is engaged in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The firm targets five indications: obstructive sleep apnea (OSA), traumatic brain injury and concussion (TBI), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and inflammatory lung conditions. Its drug candidates include IHL-42X, IHL-216A, Psilocybin-assisted psychotherapy for general anxiety disorder (Psi-GAD) and IHL-675A. Its IHL-42X is a cannabinoid combination product for treatment of OSA. Its IHL-675A comprises a combination of hydroxychloroquine and CBD for prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel diseases. IHL-216A is a cannabinoid combination product for the treatment of TBI. The company is investigating the use of psilocybin-assisted psychotherapy to treat GAD.